Member Info for Aldebaran

I am for the patients. Aren't you?

Im sure with 3 patients treated and such excellent results big farmer are all over them, queuing up with there check books sound familiar?

Ultimately its early stage and there remains a lot of clinical, financial, regulatory & competition risks but like hemo. Shows early promise. Thats it.

The rampers here outsource all there scientific research to Haywain so their totally in the dark. Ultimately hemo could easily fail and go to zero. 90% of new drugs dont make it. Thats were avacta shines, chance of success near 90% and has 90% of solid tumours to target with a whole multitude of different warheads unlike hemo that has this one shot and thats it.

Ive tried telling you 🤷🏾

Dya wanna be right, or rich?

Tick tock

In vivo CAR T using 3rd Gen Lentivirus

Anti CD3 antibody on surface enabling in vivo viral entry to CD3+ T cells generating in vivo CAR

Three patients

No LD chemo

Manageable CRS

No ICANS

All MRD Neg at month 1

Qihan Biotech are knocking it out the park it seems with faster & simpler delivery, cheaper, more scalable alternative to autologous CAR-T with even milder side effects.

You must be all buzzing considering this news for patients. It is all about the patients after all?

I realise it totally destroys HG-CT-1 but you won't care about that will you. All about the patience right.

Late breaking still a big deal or only if its hemo, not so much a big deal for another company?

I really hope HG-CT-1 is as good as its cracked up to be and if it is i hope it becomes standard of care ASAP. I think what weve seen so far is encouraging.

Long road ahead though and the above can still happen without long term holders making any money at all. You need to separate the 2. The altruistic philanthropic life saving potential which we all want and the investment case.

If you were doing this purely for philanthropist reasons you would donate your time and money direct to hemo or to family's affected or to hospitals.

So let's be right, your doing this to make money and your losing thats why your so mad. And your judgement is clouded.

Tell me, if HEMO go to 1p per share due to dilution at the point when big farmer buy it (hypothetically). Then the treatment still gets where it needs to be so what's the big deal? If it's all about altruism

Quick recap of everything I've said just to balance out Saints post.

I said at 7m market cap company was at risk of delisting.

I said if price brakes 180p with volume or funding news comes then that would be a buy signal which it was

I said resistance would be 1600p which it was

I said price would pullback initially to around 1000p which it did.

I said that first batch of warrants hadn't been forward sold which was proved to be correct

Ive calculated that its highly unlikely the warrants landing on the 24th have all been forward sold and im sure ill be proven correct.

I said BP won't do a deal off 3 patients and that was correct

I said cash burn would increase to around 500k per month with us treating 2 patience per month which turned out correct

I said Vlad should of done a raise off the back of last spike which clearly now you all see he should.

Im now saying price will test 500p but yall dont want to hear that so its dismissed. Tbh this incoming placing could see it fall further than that but as ever we will see what price action tells us. £8m is the MINIMUM the company needs. Still 320k warrants outstanding and on 24th even more warrants hit the market.

Not looking great short term is it

Quick recap of everything I've said just to balance out Saints post.

I said at 7m market cap company was at risk of delisting.

I said if price brakes 180p with volume or funding news comes then that would be a buy signal which it was

I said resistance would be 1600p which it was

I said price would pullback initially to around 1000p which it did.

I said that first batch of warrants hadn't been forward sold which was proved to be correct

Ive calculated that its highly unlikely the warrants landing on the 24th have all been forward sold and im sure ill be proven correct.

I said BP won't do a deal off 3 patients and that was correct

I said cash burn would increase to around 500k per month with us treating 2 patience per month which turned out correct

I said Vlad should of done a raise off the back of last spike which clearly now you all see he should.

Im now saying price will test 500p but yall dont want to hear that so its dismissed. Tbh this incoming placing could see it fall further than that but as ever we will see what price action tells us. £8m is the MINIMUM the company needs. Still 320k warrants outstanding and on 24th even more warrants hit the market.

Not looking great short term is it

JK Rowling has nothing on your imagination JHFH

Its all just one big conspiracy against hemo isnt it.

Hedge, why you lying? Hemo do not have 3 CLINICAL assets at all.

They have HG-CT-1 which is clinical then FLT3-CD3 bispecific antibody (CDX) and the Chimeric Bait Receptor (CBR) platform are pretty clinical.

Stop misleading people.

Basically those pre clinical assets are nothing more than molecules at the bottom of a test tube. Theyre worth pennies on the dollar.

Still no answer JHFH....

🧐

JHFH my God give it a rest. You are obsessed with shorts youre like captain Ahab !

Would you agree with me now that the latest batch of warrants weren't all forward sold? Are you going to have the humility to admit you were wrong. AGAIN ?

Also, when are you going to answer the basic question of funding. If you can provide Vlad the money, why aren't you doing it now? Surely if price is a bargain in your eyes and the only way is up and multiple big farmer are chomping at the bit to lavish vlad in cash it makes sense for you to burn those shorters you hate so much to smithereens? Why aren't you?

Genuine question. Im sure more than I would like you to answer and if you dont all I can assume is that your full of it again.

If you had the kind of money hemo need, plus what you already put in, you'd have took company private in July when it was 7m market cap.

There is no rescue finance for vlad and there is no BP going to throw huge sums at him of the back of 3 patience data.

It will either be back to monthly placings or a large discounted placing.

Shame vlad didnt have the foresight to raise during the last spike like I suggested he should. How many of you truly wish he had now with hindsight? Honestly?

JRDC 👏

I agree with that post 100%

You're deluded.

When shorts close they cause buying pressure. If they were closing like youre saying price would be UP not breaking down through the 100dma.

You might not like what I say, but it doesnt make it untrue.

Rather than debate though and prove me wrong (because you cant), you just start the accusations, trying and bury posts, have posts removed, question the motive behind posting without even trying to understand another point of view.

Thats to your detriment. Anyway, onwards and downwards chuck. Speak soon. P.s. avacta in the buyzon. Remember I told you all that today. I said it at 52p. And im saying it again now at low 70's. Remember I told u.

Over and out

Quick recap of everything I've said just to balance out Saints post.

I said at 7m market cap company was at risk of delisting.

I said if price brakes 180p with volume or funding news comes then that would be a buy signal which it was

I said resistance would be 1600p which it was

I said price would pullback initially to around 1000p which it did.

I said that first batch of warrants hadn't been forward sold which was proved to be correct

Ive calculated that its highly unlikely the warrants landing on the 24th have all been forward sold and im sure ill be proven correct.

I said BP won't do a deal off 3 patients and that was correct

I said cash burn would increase to around 500k per month with us treating 2 patience per month which turned out correct

I said Vlad should of done a raise off the back of last spike which clearly now you all see he should.

Im now saying price will test 500p but yall dont want to hear that so its dismissed. Tbh this incoming placing could see it fall further than that but as ever we will see what price action tells us. £8m is the MINIMUM the company needs. Still 320k warrants outstanding and on 24th even more warrants hit the market.

Not looking great short term is it

Garonne. 2027 at the earliest is when this has a chance of being investable.

For anyone that prefers money to jam, AVCT just completing its latest PB from the 80's to 75p so firmly back in the dip buying phase.

Game changing news due next week. Can't say I ain't told you guys I only been highlighting it since 42p 🤪

CN no matter how much you want it to be true that any kind of news about hydrogen is going to send shares flying and any hydrogen project anywhere in the world must be using afc products im sorry but it's just not true.

As me and others posters keep trying to politely tell you. Afc need to deliver material sales just to justify the existing 100 million pound market capitalisation. We can talk about growth after that.

2027 is the year to look in here. Another huge raise required next year

Https://share.google/qFCbjKz62gmzJ9pXJ released 24th July.

91% disease control rate and at least doubling of progression free survial. In a indication with no standard of care. Yet some here want to analyse which specific blood vessels are carrying the exact molar amount of AVA6K 🙄

Results speak for themselves. Wear past this kind of FUD now.

From p1a results a couple of standout highlighted.

70yr old had a minor responses but a complete regressions of skin metastasis though that doesnt count as RECIST response it is truly remarkable. Especially as he had recieved multiple lines of prior therapy including chemo AND his tumour was not even high FAP.

79yr old male had a 45% tumour shrinkage that was "still shrinking" at data cut of.

Then we look at p1b and only snippet we have had is 1 69yr old male had a unconfirmed partial responses with 50% tumour shrinkage. This was his 1st systemic therapy also - - wonder how, he is doing now.

Avacta have raised £23m of the back of data we are yet to see. GSA close there short. Heights deferred bond payment.

Given the above snippets and the boards "growing confidence in precision" plus the astonishing results from 2nd and 3rd gen pre clinical assets I'd suggest the results are already exceptional and p1b will knock it out the park. I expect the full potential of dox to be released and responses proportional to the patients current health and prior lines of therapy.

200m pa indication right here in sight and within grasp.

Shall we let the PHD scientists in charge of the company worry about the fine details perhaps. Its what they're paid to do and trained for their entire lives after all.

91% disease control rate

Doubling of progression free survival rate

1 or 2 partial responses

Multiple minor responses

Complete regressions of skin metastasis

The above achieved in heavily pre treated and sick patience with chemotherapy refractory tumours. Some of these treat with less than optimal dose of AVA6K also.

Current treatment options = NONE

Peak sales estimate £200m

Now treating between 10 & 30 SGC patience since Q1 this year with exact same drug. This patient population includes much healthier patients, less treatment and cancers that have not developed resistance to chemotherapy yet.

The board said that they are increasingly encouraged by the efficacy signals and that this is of interest to big pharma. HNWI's introduced through RH chucked in £7m in two tranches then HNWI & instituons chucked in £16m at 63p and you can be sure they know more than us.

Heights deferred the bond payment by over a year on the back of the data we haven't seen yet.

GSA closes their short out.

But sure, let's start worrying about how much blood is going through an individual vein at any moment in time 🙄

Last post on the subject and I totally agree these guys are here purely to spread FUD. Not worth engaging with whatsoever

What on earth does any of this matter when patients are only complaining that they are tired from treatment and all toxicities are reduced and cardiotoxicity eliminated altogether and were seeing over 90% disease control rate, cleaning up of skin metastasis which can't be measured as RECIST response and seeing durability.

The results literally speak for themselves despite which way round the blood is flowing etc your analysing this down to the far end of a fart for what reason

I imagine the £16m raised at 63p from HNWI's and institutes were given certain assurances.

Remember avacta have raided around £7m before that in 2 tranches from HNWI's all connected to RH also. Im sure he knows what hes doing.

GSA closed their short for a, reason.

Heights allowed deferment of the bond payment for a reason.

The data for SGC is already exceptional. In really sick patients. Its already exceptional.

Just presenting more of the same but in a bigger patient population would be great but its likely the data will be better because some of the patients included have had much less treatment, are much less chemo resistant tunours.

This data set will inform on ACCELERATED APPROVAL pathways. Avacta also guided that ODD could be granted for 6k in this indication by year end also. The data is already good enough considering nccn guidelines show nil treatment options.

What are you fretting about and trying to sow FUD? 🤡

I dont know why anybody bothers engaging with this parasite I really don't. We didnt get standalone breakthrough RNS's for p1a patients, even when the skin metastasis cleared up. Avacta deliver news to us in a controlled way via planned investor events.

This p1b population still contains many sick patients who have had previous treatment, maybe there is a handful of 1st line patients in but im expecting a marginal increase on the ALREADY EXCEPTIONAL P1a.

We been told big farmer are waiting for this data and it will inform on accelerated approval pathways. The board are increasingly confident in the data.

We raised £16m in a oversubscribed placing recently and heights deferred the bond payment. All on the back of data.

There is no standard of care for metastatic SGC so even if P1B "only" replicates what P1a showed, that's more than enough lol

But it won't, it will be a better data set commensurate with the starting health condition & prior treatments of the patience.

Wyn seems like the type to worry whether the sun will rise each day, despite doing it every day since Earth was formed billions of years ago. I supposed you just never can be 100% sure can you

🤣🤡

Don't feed into him. He'll have sold a load of not all and hoping Rachael Reeves causes further falls in share prices this week where He'll pick them up again cheaper ready for the results. Scratting around for pennies again like the parasite he is.

Yes data release and investor webinar all within next 2 weeks. Maybe first week of Dec right after the USA holidays for max impact. This likely the last 5 days we're you can buy shares around this level so folks will need to make most of it.